Regina I Jakacki

Summary

Affiliation: Children's Hospital of Pittsburgh
Country: USA

Publications

  1. ncbi A pilot study of preirradiation chemotherapy and 1800 cGy craniospinal irradiation in young children with medulloblastoma
    Regina I Jakacki
    Division of Pediatric Hematology Oncology, Children s Hospital of Pittsburgh, Pittsburgh, PA, USA
    Int J Radiat Oncol Biol Phys 60:531-6. 2004
  2. ncbi Treatment strategies for high-risk medulloblastoma and supratentorial primitive neuroectodermal tumors. Review of the literature
    Regina I Jakacki
    Division of Pediatric Hematology Oncology, Children s Hospital of Pittsburgh, Pennsylvania 15213, USA
    J Neurosurg 102:44-52. 2005
  3. ncbi Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: a Children's Oncology Group Phase I/II study
    Regina I Jakacki
    Children s Hospital of Pittsburgh, 4401 Penn Ave, Pittsburgh, PA 15224, USA
    J Clin Oncol 30:2648-53. 2012
  4. ncbi Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study
    Regina I Jakacki
    Children s Hospital of Pittsburgh, Pittsburgh, PA 15213, USA
    J Clin Oncol 26:4921-7. 2008
  5. ncbi Phase I trial of pegylated interferon-alpha-2b in young patients with plexiform neurofibromas
    R I Jakacki
    Children s Hospital of Pittsburgh, 4401 Penn Avenue, Pittsburgh, PA 15224, USA
    Neurology 76:265-72. 2011
  6. ncbi A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood
    Regina I Jakacki
    Children s Hospital of Pittsburgh, Pittsburgh, PA 15213, USA
    Neuro Oncol 10:569-76. 2008
  7. ncbi A phase 1 study of vinblastine in combination with carboplatin for children with low-grade gliomas: a Children's Oncology Group phase 1 consortium study
    Regina I Jakacki
    Children s Hospital of Pittsburgh, Pittsburgh, PA 15224, USA
    Neuro Oncol 13:910-5. 2011
  8. ncbi IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children's Oncology Group
    Ian F Pollack
    Department of Neurosurgery, Children s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, 4401 Penn Avenue, Pittsburgh, PA 15224, USA
    Childs Nerv Syst 27:87-94. 2011
  9. ncbi Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group
    Ian F Pollack
    Department of Neurosurgery, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Pediatr Blood Cancer 55:1066-71. 2010
  10. ncbi Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the Children's Oncology Group
    Ian F Pollack
    Department of Neurosurgery, Children s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, 4401 Penn Avenue, Pittsburgh, PA 15224, USA
    J Neurooncol 99:155-63. 2010

Detail Information

Publications19

  1. ncbi A pilot study of preirradiation chemotherapy and 1800 cGy craniospinal irradiation in young children with medulloblastoma
    Regina I Jakacki
    Division of Pediatric Hematology Oncology, Children s Hospital of Pittsburgh, Pittsburgh, PA, USA
    Int J Radiat Oncol Biol Phys 60:531-6. 2004
    ..We prospectively evaluated the feasibility of giving preirradiation chemotherapy followed by 1800 cGy CSI to young children with localized medulloblastoma...
  2. ncbi Treatment strategies for high-risk medulloblastoma and supratentorial primitive neuroectodermal tumors. Review of the literature
    Regina I Jakacki
    Division of Pediatric Hematology Oncology, Children s Hospital of Pittsburgh, Pennsylvania 15213, USA
    J Neurosurg 102:44-52. 2005
    ..The author reviews the literature, describes currently available treatment options for patients with high-risk PNETs, and discusses strategies aimed at improving outcome and refining prognosis that are currently being explored...
  3. ncbi Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: a Children's Oncology Group Phase I/II study
    Regina I Jakacki
    Children s Hospital of Pittsburgh, 4401 Penn Ave, Pittsburgh, PA 15224, USA
    J Clin Oncol 30:2648-53. 2012
    ....
  4. ncbi Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study
    Regina I Jakacki
    Children s Hospital of Pittsburgh, Pittsburgh, PA 15213, USA
    J Clin Oncol 26:4921-7. 2008
    ..We conducted a phase I and pharmacokinetic study of the epidermal growth factor receptor (EGFR) inhibitor erlotinib as a single agent and in combination with temozolomide in children with refractory solid tumors...
  5. ncbi Phase I trial of pegylated interferon-alpha-2b in young patients with plexiform neurofibromas
    R I Jakacki
    Children s Hospital of Pittsburgh, 4401 Penn Avenue, Pittsburgh, PA 15224, USA
    Neurology 76:265-72. 2011
    ..We sought to evaluate preliminary efficacy and determine the recommended phase II dose (RP2D) for pegylated interferon-α-2b (PI) in patients with unresectable progressive or symptomatic plexiform neurofibromas (PN)...
  6. ncbi A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood
    Regina I Jakacki
    Children s Hospital of Pittsburgh, Pittsburgh, PA 15213, USA
    Neuro Oncol 10:569-76. 2008
    ..Radiographic changes following RT make determination of early tumor progression difficult. Metastatic disease is common prior to death...
  7. ncbi A phase 1 study of vinblastine in combination with carboplatin for children with low-grade gliomas: a Children's Oncology Group phase 1 consortium study
    Regina I Jakacki
    Children s Hospital of Pittsburgh, Pittsburgh, PA 15224, USA
    Neuro Oncol 13:910-5. 2011
    ..The recommended phase 2 dose and schedule is carboplatin, 400 mg/m(2)/dose on day 1, and vinblastine, 4 mg/m(2)/dose, weekly × 3, repeated every 4 weeks. Further study of this regimen in patients with low-grade glioma is warranted...
  8. ncbi IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children's Oncology Group
    Ian F Pollack
    Department of Neurosurgery, Children s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, 4401 Penn Avenue, Pittsburgh, PA 15224, USA
    Childs Nerv Syst 27:87-94. 2011
    ..Because pediatric malignant gliomas share some molecular features with adult secondary gliomas, we questioned whether a subset of these tumors also exhibited IDH mutations...
  9. ncbi Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group
    Ian F Pollack
    Department of Neurosurgery, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Pediatr Blood Cancer 55:1066-71. 2010
    ..However, the frequency of this abnormality as a clinical resistance mechanism in childhood malignant gliomas has not been well characterized...
  10. ncbi Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the Children's Oncology Group
    Ian F Pollack
    Department of Neurosurgery, Children s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, 4401 Penn Avenue, Pittsburgh, PA 15224, USA
    J Neurooncol 99:155-63. 2010
    ..In view of the frequency of Akt activation, the evaluation of molecularly targeted therapies that inhibit this pathway warrants consideration for these tumors...
  11. ncbi Pegylated interferon-α-2b for children with recurrent craniopharyngioma
    Jacky T Yeung
    Department of Neurosurgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15224, USA
    J Neurosurg Pediatr 10:498-503. 2012
    ..Pegylaion of interferon-α-2b (PI) prolongs the half-life, allowing sustained exposure of the drug over time, and enhances efficacy. The authors report the results of the use of PI in 5 children with recurrent craniopharyngiomas...
  12. ncbi Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report
    Ian F Pollack
    Department of Neurosurgery, Children s Hospital of Pittsburgh, 3705 Fifth Avenue, Pittsburgh, PA 15213, USA
    Neuro Oncol 9:145-60. 2007
    ..Imatinib may increase the risk of ITH, although the incidence of spontaneous hemorrhages in brainstem glioma is sufficiently high that this should be considered in studies of agents in which hemorrhage is a concern...
  13. ncbi A novel SNP analysis method to detect copy number alterations with an unbiased reference signal directly from tumor samples
    Alex Lisovich
    Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    BMC Med Genomics 4:14. 2011
    ....
  14. ncbi Stereotactic radiosurgery for pilocytic astrocytomas part 2: outcomes in pediatric patients
    Hideyuki Kano
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, Suite B 400, UPMC Presbyterian, 200 Lothrop Street, Pittsburgh, PA 15213, USA
    J Neurooncol 95:219-29. 2009
    ..Stereotactic radiosurgery for pediatric pilocytic astrocytomas should be considered when resection is not feasible, or if there is an early recurrence. The best response was observed in small volume residual solid tumors...
  15. ncbi Childhood brain tumors: epidemiology, current management and future directions
    Ian F Pollack
    Department of Neurosurgery, Children s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, 4401 Penn Avenue, Pittsburgh, PA 15224, USA
    Nat Rev Neurol 7:495-506. 2011
    ..The latest insights from molecular correlative studies that hold potential for future refinements in therapy will also be discussed...
  16. ncbi Increased expression of tumor-associated antigens in pediatric and adult ependymomas: implication for vaccine therapy
    Jacky T Yeung
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    J Neurooncol 111:103-11. 2013
    ..Pediatric and adult ependymomas frequently express EphA2, IL-13Rα2, and Survivin. This provides the basis for the utilization of an established multiple peptide vaccine for ependymoma in a clinical trial setting...
  17. ncbi Optic pathway glioma as part of a constitutional mismatch-repair deficiency syndrome in a patient meeting the criteria for neurofibromatosis type 1
    Jacky T Yeung
    Doris Duke Clinical Research Fellowship, Department of Neurosurgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Pediatr Blood Cancer 60:137-9. 2013
    ..We report the case of a 3-year-old male with an extensive OPG who met the diagnostic criteria for NF-1. He was subsequently found to have multiple colonic polyps and bi-allelic loss of PMS2. Testing for NF-1 was negative...
  18. ncbi Extraventricular neurocytoma in neurofibromatosis Type 1: case report
    Ali I Raja
    Department of Neurosurgery, Children s Hospital of Pittsburgh, Pittsburgh, PA 15213, USA
    J Neurosurg Pediatr 2:63-7. 2008
    ..The importance of obtaining a biopsy in lesions that have atypical imaging features is highlighted...
  19. ncbi Patterns of failure after induction chemotherapy followed by consolidative radiation therapy for children with central nervous system germinoma
    Robert D Timmerman
    Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, Indiana, IN 46202, USA
    Med Pediatr Oncol 41:564-6. 2003